General
Preferred name
DROXIDOPA
Synonyms
L-DOPS ()
DOPS ()
SM5688 ()
L-threo-dops ()
Northera ()
P&D ID
PD014696
CAS
3916-18-5
1260173-94-1
23651-95-8
Tags
available
prodrug
drug
Approved by
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Neurogenic orthostatic hypotension
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
As droxidopa is a prodrug for noradrenaline, its effects will be through noradrenaline activation of adrenoceptors. The cellular effect is dependent upon adrenoceptor subtype expression on target cells.
(GtoPdb)
MOA
Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
38
Molecular Weight
213.06
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
5
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.46
TPSA
124.01
Fraction CSP3
0.22
Chiral centers
2.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Adrenergic Receptor inhibitor
Norepinephrine Precursors
norepinephrine precursor
Pathway
Neuroscience
GPCR/G protein
Neuronal Signaling
Member status
virtual
Indication
hypertension, Parkinson's Disease
Disease Area
cardiology, neurology/psychiatry
Target
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH
Adrenergic Receptor
Source data
